HC Wainwright Reaffirms “Buy” Rating for X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $1.50 price target on the stock. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.15 EPS.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $3.00 target price on shares of X4 Pharmaceuticals in a research report on Wednesday.

X4 Pharmaceuticals Price Performance

Shares of X4 Pharmaceuticals stock opened at $0.25 on Thursday. The firm has a market capitalization of $43.42 million, a PE ratio of -2.78 and a beta of 0.39. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 12 month low of $0.24 and a 12 month high of $1.60. The business’s 50-day moving average price is $0.43 and its 200-day moving average price is $0.52.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Tuesday, March 25th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.07 million. Sell-side analysts forecast that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the transaction, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders have sold a total of 202,663 shares of company stock worth $91,198 in the last 90 days. 1.62% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Acorn Capital Advisors LLC bought a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth about $5,363,000. JPMorgan Chase & Co. increased its stake in X4 Pharmaceuticals by 501.0% in the fourth quarter. JPMorgan Chase & Co. now owns 459,653 shares of the company’s stock worth $337,000 after purchasing an additional 383,177 shares during the period. Jane Street Group LLC lifted its holdings in X4 Pharmaceuticals by 134.9% during the 4th quarter. Jane Street Group LLC now owns 583,483 shares of the company’s stock valued at $428,000 after buying an additional 335,036 shares in the last quarter. Deutsche Bank AG boosted its position in X4 Pharmaceuticals by 559.6% in the 4th quarter. Deutsche Bank AG now owns 267,628 shares of the company’s stock valued at $195,000 after buying an additional 227,051 shares during the period. Finally, State Street Corp grew its stake in X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after acquiring an additional 189,105 shares in the last quarter. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.